KR100403900B1 - 누클레오시드 유사체의 합성 방법 - Google Patents

누클레오시드 유사체의 합성 방법 Download PDF

Info

Publication number
KR100403900B1
KR100403900B1 KR10-2000-0024885A KR20000024885A KR100403900B1 KR 100403900 B1 KR100403900 B1 KR 100403900B1 KR 20000024885 A KR20000024885 A KR 20000024885A KR 100403900 B1 KR100403900 B1 KR 100403900B1
Authority
KR
South Korea
Prior art keywords
substituted
group
dmso
hydrogen
alkylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2000-0024885A
Other languages
English (en)
Korean (ko)
Other versions
KR20010069193A (ko
Inventor
로버트 윌리암 스코트
Original Assignee
화이자 프로덕츠 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 프로덕츠 인크. filed Critical 화이자 프로덕츠 인크.
Publication of KR20010069193A publication Critical patent/KR20010069193A/ko
Application granted granted Critical
Publication of KR100403900B1 publication Critical patent/KR100403900B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-2000-0024885A 1999-05-11 2000-05-10 누클레오시드 유사체의 합성 방법 Expired - Fee Related KR100403900B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13365199P 1999-05-11 1999-05-11
US60/133,651 1999-05-11

Publications (2)

Publication Number Publication Date
KR20010069193A KR20010069193A (ko) 2001-07-23
KR100403900B1 true KR100403900B1 (ko) 2003-11-01

Family

ID=22459680

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-0024885A Expired - Fee Related KR100403900B1 (ko) 1999-05-11 2000-05-10 누클레오시드 유사체의 합성 방법

Country Status (22)

Country Link
US (1) US6271370B1 (en:Method)
EP (1) EP1052264B1 (en:Method)
JP (1) JP2001011092A (en:Method)
KR (1) KR100403900B1 (en:Method)
CN (1) CN1275575A (en:Method)
AR (1) AR028991A1 (en:Method)
AT (1) ATE291582T1 (en:Method)
AU (1) AU3401100A (en:Method)
BR (1) BR0002089A (en:Method)
CA (1) CA2307951A1 (en:Method)
CZ (1) CZ20001710A3 (en:Method)
DE (1) DE60018833D1 (en:Method)
HU (1) HUP0001843A3 (en:Method)
ID (1) ID25992A (en:Method)
IL (1) IL136027A0 (en:Method)
IN (1) IN186850B (en:Method)
MX (1) MXPA00004532A (en:Method)
PL (1) PL340109A1 (en:Method)
RU (1) RU2200738C2 (en:Method)
TR (1) TR200001340A2 (en:Method)
YU (1) YU25500A (en:Method)
ZA (1) ZA200002263B (en:Method)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PT1773856E (pt) * 2004-07-21 2012-05-14 Gilead Pharmasset Llc Preparação de 2-desoxi-2-fluoro-d-ribofuranosilo pirimidinas e purinas substituídas com alquilo e seus derivados
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
AU2006244195B2 (en) * 2005-05-05 2012-03-15 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
US8207178B2 (en) * 2007-12-14 2012-06-26 Ardea Biosciences, Inc. Fused pyrimidines as reverse transcriptase inhibitors
US8394836B2 (en) 2007-12-14 2013-03-12 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
MA33128B1 (fr) 2009-02-17 2012-03-01 Chiesi Farma Spa Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase
WO2011005860A2 (en) * 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012003709B1 (pt) 2009-08-17 2021-05-18 Intellikine Llc compostos heterocíclicos e usos dos mesmos
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
CA2858420A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
SG11201402986RA (en) 2011-12-09 2014-12-30 Chiesi Farma Spa Kinase inhibitors
AU2012347350C1 (en) 2011-12-09 2017-01-19 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
SG11201408044QA (en) 2012-06-29 2015-01-29 Pfizer NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
US9181242B2 (en) 2013-06-06 2015-11-10 Chiesi Farmaceutici S.P.A. Kinase inhibitors
KR20160050080A (ko) 2013-09-05 2016-05-10 에프. 호프만-라 로슈 아게 트라이아졸로피리딘 화합물, 이의 조성물 및 사용 방법
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
CN107428750A (zh) 2015-03-04 2017-12-01 豪夫迈·罗氏有限公司 三唑并吡啶化合物及其使用方法
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
WO2017108738A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urea derivatives and their use as p38 mapk inhibitors
AR107163A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
CN109476638B (zh) 2016-05-05 2021-12-28 豪夫迈·罗氏有限公司 吡唑衍生物、其组合物及治疗用途
CA3035712A1 (en) 2016-09-06 2018-03-15 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
BR112019013287A2 (pt) 2016-12-29 2019-12-24 Hoffmann La Roche compostos de pirazolopirimidina e métodos de uso dos mesmos
CN110494434B (zh) 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 吡唑并氯苯基化合物、其组合物及其使用方法
RU2769696C2 (ru) 2017-05-22 2022-04-05 Ф. Хоффманн-Ля Рош Аг Терапевтические соединения и композиции и способы их применения
CN110678467B (zh) 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
JP7339263B2 (ja) 2018-01-15 2023-09-05 エフ． ホフマン－ラ ロシュ アーゲー Ｊａｋ阻害剤としてのピラゾロピリミジン化合物
JP7768505B2 (ja) 2018-06-01 2025-11-12 コーネル・ユニバーシティー Ｐｉ３ｋに関連する疾患または障害に対する併用療法
BR112021025618A2 (pt) 2019-06-18 2022-02-01 Hoffmann La Roche Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto
TW202115069A (zh) 2019-06-18 2021-04-16 瑞士商赫孚孟拉羅股份公司 Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途
CN114008050B (zh) 2019-06-18 2024-12-31 豪夫迈·罗氏有限公司 Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN117343119A (zh) * 2022-06-29 2024-01-05 上海交通大学 一种烷基化核苷、核苷酸、寡核苷酸及其类似物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207400A (ja) * 1985-03-11 1986-09-13 Nippon Zoki Pharmaceut Co Ltd ヌクレオシド化合物の製造方法
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4859677A (en) 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5246931A (en) 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5470857A (en) 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
WO1996004293A1 (en) * 1994-08-02 1996-02-15 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5659023A (en) 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
TR199801431T2 (xx) 1996-01-23 1998-10-21 The Regents Of The University Of Michigan Antiviral aktif maddeler olarak de�i�tirilmi� benzimidazol n�kleosidler.

Also Published As

Publication number Publication date
YU25500A (sh) 2003-08-29
EP1052264B1 (en) 2005-03-23
ID25992A (id) 2000-11-16
US6271370B1 (en) 2001-08-07
EP1052264A2 (en) 2000-11-15
CZ20001710A3 (cs) 2001-09-12
CA2307951A1 (en) 2000-11-11
HU0001843D0 (en) 2000-07-28
EP1052264A3 (en) 2001-06-13
BR0002089A (pt) 2001-01-02
DE60018833D1 (de) 2005-04-28
RU2200738C2 (ru) 2003-03-20
HUP0001843A3 (en) 2001-09-28
KR20010069193A (ko) 2001-07-23
ATE291582T1 (de) 2005-04-15
AR028991A1 (es) 2003-06-04
MXPA00004532A (es) 2002-03-08
PL340109A1 (en) 2000-11-20
HUP0001843A2 (hu) 2001-06-28
ZA200002263B (en) 2001-12-24
IL136027A0 (en) 2001-05-20
IN186850B (en:Method) 2001-11-24
CN1275575A (zh) 2000-12-06
TR200001340A2 (tr) 2000-12-21
JP2001011092A (ja) 2001-01-16
AU3401100A (en) 2000-11-16

Similar Documents

Publication Publication Date Title
KR100403900B1 (ko) 누클레오시드 유사체의 합성 방법
JP4451983B2 (ja) ヌクレオシド代謝の阻害剤
JP2675749B2 (ja) デスアザプリン−ヌクレオシド−誘導体
US7109331B2 (en) 5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors
Reist et al. Potential anticancer agents. 1 LXXVI. Synthesis of purine nucleosides of β-D-arabinofuranose
US20090005551A1 (en) Synthesis of 5-azacytidine
WO2011003018A9 (en) Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof
US4140851A (en) Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides
US4968690A (en) 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
JPH03170496A (ja) デオキシフルオロヌクレオシドの製造法
WO2007047793A2 (en) Cyclopentenol nucleoside compounds, intermediates for their synthesis and methods of treating viral infections
KR20040031784A (ko) Ｌ-리바비린의 제조 방법
US3201387A (en) 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
JP2003522798A (ja) ２−クロロ−９−（２−デオキシ−２−フルオロ−β−Ｄ−アラビノフラノシル）−９Ｈ−プリン−６−アミンの合成方法
Minakawa et al. Nucleosides and nucleotides. 116. Convenient syntheses of 3-deazaadenosine, 3-deazaguanosine, and 3-deazainosine via ring closure of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide or-carbonitrile
EP0389110B1 (en) Process for the preparation of 2'-deoxy-5-trifluoromethyl-beta-uridine
EP0638586A2 (en) Nucleoside derivatives and methods for producing them
Hancox et al. Some reactions of 4′-thionucleosides and their sulfones
Cook et al. Synthesis of the Natural Product 5'-Deoxy-5-iodotubercidin and Related Halogenated Analogs
JP3202234B2 (ja) ２−フルオルプリン誘導体の新規製法
IE920106A1 (en) Process for the preparation of 3'-fluoropyrimidine¹nucleosides
HK1033138A (en) Process for the synthesis of nucleoside analogs
Sivets et al. Synthesis of 2-Chloro-2′-Deoxyadenosine (Cladribine) and New Purine Modified Analogues
JPH0446244B2 (en:Method)
WO2020263660A1 (en) Process for the preparation of 2-fluoroadenine

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20061021

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20061021

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000